IP Verse

Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody

Patent No. EP3288980 (titled "Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody") was filed by Bristol Myers Squibb on Apr 28, 2016. The application was issued on Mar 10, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GREINERDec 10, 2021GREINER
POHLMANDec 10, 2021POHLMAN
PAJARODec 9, 2021BIRD & BIRD
KRAUS & LEDERER PARTGMBBDec 8, 2021KRAUS & LEDERER PARTGMBB
DR H ULRICH DORRIESDec 7, 2021DORRIES
DR H ULRICH DORRIESDec 7, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3288980

BRISTOL MYERS SQUIBB
Application Number
EP16724512A
Filing Date
Apr 28, 2016
Status
Granted And Under Opposition
Feb 5, 2021
Publication Date
Mar 10, 2021
External Links
Slate, Register , Google Patents